{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,7,20]],"date-time":"2025-07-20T03:59:38Z","timestamp":1752983978045},"reference-count":29,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2018,9,10]],"date-time":"2018-09-10T00:00:00Z","timestamp":1536537600000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Int J Hematol"],"published-print":{"date-parts":[[2019,1]]},"DOI":"10.1007\/s12185-018-2526-z","type":"journal-article","created":{"date-parts":[[2018,9,10]],"date-time":"2018-09-10T04:25:15Z","timestamp":1536553515000},"page":"91-97","update-policy":"http:\/\/dx.doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":5,"title":["Tumor long-axis diameter and SUVmax predict long-term responders in 90Y-ibritumomab tiuxetan monotherapy"],"prefix":"10.1007","volume":"109","author":[{"given":"Norifumi","family":"Tsukamoto","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Akihiko","family":"Yokohama","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tetsuya","family":"Higuchi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Takeki","family":"Mitsui","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hiromi","family":"Koiso","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Makiko","family":"Takizawa","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hiroaki","family":"Shimizu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Takuma","family":"Ishizaki","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Morio","family":"Matsumoto","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kohtaro","family":"Toyama","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tohru","family":"Sakura","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hidemi","family":"Ogura","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Takayuki","family":"Saitoh","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Fumihiro","family":"Ishida","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hirokazu","family":"Murakami","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yoshito","family":"Tsushima","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hiroshi","family":"Handa","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2018,9,10]]},"reference":[{"key":"2526_CR1","doi-asserted-by":"publisher","first-page":"8447","DOI":"10.1200\/JCO.2005.03.1674","volume":"23","author":"RI Fisher","year":"2005","unstructured":"Fisher RI, LeBlanc M, Press OW, Maloney DG, Unger JM, Miller TP. New treatment options have changed the survival of patients with follicular lymphoma. J Clin Oncol. 2005;23:8447\u201352.","journal-title":"J Clin Oncol"},{"key":"2526_CR2","doi-asserted-by":"publisher","first-page":"268","DOI":"10.1200\/JCO.1999.17.1.268","volume":"17","author":"MS Czuczman","year":"1999","unstructured":"Czuczman MS, Grillo-L\u00f3pez AJ, White CA, Saleh M, Gordon L, LoBuglio AF, et al. Treatment of patients with low-grade B-cell lymphoma with the combination of chimeric anti-CD20 monoclonal antibody and CHOP chemotherapy. J Clin Oncol. 1999;17:268\u201376.","journal-title":"J Clin Oncol"},{"key":"2526_CR3","doi-asserted-by":"publisher","first-page":"3990","DOI":"10.1200\/JCO.2011.34.8508","volume":"29","author":"T Watanabe","year":"2011","unstructured":"Watanabe T, Tobinai K, Shibata T, Tsukasaki K, Morishima Y, Maseki N, et al. Phase II\/III study of R-CHOP-21 versus R-CHOP-14 for untreated indolent B-cell non-Hodgkin\u2019s lymphoma: JCOG 0203 trial. J Clin Oncol. 2011;29:3990\u20138.","journal-title":"J Clin Oncol"},{"key":"2526_CR4","doi-asserted-by":"publisher","first-page":"4473","DOI":"10.1200\/JCO.2008.17.0001","volume":"26","author":"KS Robinson","year":"2008","unstructured":"Robinson KS, Williams ME, van der Jagt RH, Cohen P, Herst JA, Tulpule A, et al. Phase II multicenter study of bendamustine plus rituximab in patients with relapsed indolent B-cell and mantle cell non-Hodgkin\u2019s lymphoma. J Clin Oncol. 2008;26:4473\u20139.","journal-title":"J Clin Oncol"},{"key":"2526_CR5","doi-asserted-by":"publisher","first-page":"174","DOI":"10.1200\/JCO.2005.03.9313","volume":"24","author":"K Tobinai","year":"2006","unstructured":"Tobinai K, Watanabe T, Ogura M, Morishima Y, Ogawa Y, Ishizawa K, et al. Phase II study of oral fludarabine phosphate in relapsed indolent B-Cell non-Hodgkin\u2019s lymphoma. J Clin Oncol. 2006;24:174\u201380.","journal-title":"J Clin Oncol"},{"key":"2526_CR6","doi-asserted-by":"publisher","first-page":"2453","DOI":"10.1200\/JCO.2002.11.076","volume":"20","author":"TE Witzig","year":"2002","unstructured":"Witzig TE, Gordon LI, Cabanillas F, Czuczman MS, Emmanouilides C, Joyce R, et al. Randomized controlled trial of yttrium-90-labeled ibritumomab tiuxetan radioimmunotherapy versus rituximab immunotherapy for patients with relapsed or refractory low-grade, follicular, or transformed B-cell non-Hodgkin\u2019s lymphoma. J Clin Oncol. 2002;20:2453\u201363.","journal-title":"J Clin Oncol"},{"key":"2526_CR7","doi-asserted-by":"publisher","first-page":"158","DOI":"10.1111\/j.1349-7006.2008.00999.x","volume":"100","author":"K Tobinai","year":"2009","unstructured":"Tobinai K, Watanabe T, Ogura M, Morishima Y, Hotta T, Ishizawa K, et al. Japanese phase II study of 90Y-ibritumomab tiuxetan in patients with relapsed or refractory indolent B-cell lymphoma. Cancer Sci. 2009;100:158\u201364.","journal-title":"Cancer Sci"},{"key":"2526_CR8","doi-asserted-by":"publisher","first-page":"3662","DOI":"10.1002\/cncr.28243","volume":"119","author":"AM Evens","year":"2013","unstructured":"Evens AM, Vanderplas A, LaCasce AS, Crosby AL, Nademanee AP, Kaminski MS, et al. Stem cell transplantation for follicular lymphoma relapsed\/refractory after prior rituximab: a comprehensive analysis from the NCCN lymphoma outcomes project. Cancer. 2013;119:3662\u201371.","journal-title":"Cancer"},{"key":"2526_CR9","doi-asserted-by":"publisher","first-page":"3793","DOI":"10.1200\/JCO.1999.17.12.3793","volume":"17","author":"TE Witzig","year":"1999","unstructured":"Witzig TE, White CA, Wiseman GA, Gordon LI, Emmanouilides C, Raubitschek A, et al. Phase I\/II trial of IDEC-Y2B8 radioimmunotherapy for treatment of relapsed or refractory CD20(+) B-cell non-Hodgkin\u2019s lymphoma. J Clin Oncol. 1999;17:3793\u2013803.","journal-title":"J Clin Oncol"},{"issue":"Suppl 2","key":"2526_CR10","doi-asserted-by":"publisher","first-page":"4","DOI":"10.1634\/theoncologist.2009-S2-4","volume":"14","author":"SA Gregory","year":"2009","unstructured":"Gregory SA, Hohloch K, Gisselbrecht C, Tobinai K, Dreyling M. Harnessing the energy: development of radioimmunotherapy for patients with non-Hodgkin\u2019s lymphoma. Oncologist. 2009;14(Suppl 2):4\u201316.","journal-title":"Oncologist"},{"key":"2526_CR11","doi-asserted-by":"publisher","first-page":"3059","DOI":"10.1200\/JCO.2013.54.8800","volume":"32","author":"BD Cheson","year":"2014","unstructured":"Cheson BD, Fisher RI, Barrington SF, Cavalli F, Schwartz LH, Zucca E, et al. Recommendations for initial evaluation, staging, and response assessment of Hodgkin and non-Hodgkin lymphoma: the Lugano classification. J Clin Oncol. 2014;32:3059\u201368.","journal-title":"J Clin Oncol"},{"key":"2526_CR12","doi-asserted-by":"publisher","first-page":"499","DOI":"10.1007\/s12149-015-0969-3","volume":"29","author":"A Tokue","year":"2015","unstructured":"Tokue A, Higuchi T, Arisaka Y, Nakajima T, Tokue H, Tsushima Y. Role of F-18 FDG PET\/CT in assessing IgG4-related disease with inflammation of head and neck glands. Ann Nucl Med. 2015;29:499\u2013505.","journal-title":"Ann Nucl Med"},{"key":"2526_CR13","doi-asserted-by":"publisher","first-page":"1258","DOI":"10.1182\/blood-2003-12-4434","volume":"104","author":"P Solal-C\u00e9ligny","year":"2004","unstructured":"Solal-C\u00e9ligny P, Roy P, Colombat P, White J, Armitage JO, et al. Follicular lymphoma international prognostic index. Blood. 2004;104:1258\u201365.","journal-title":"Blood"},{"key":"2526_CR14","doi-asserted-by":"publisher","first-page":"4555","DOI":"10.1200\/JCO.2008.21.3991","volume":"27","author":"M Federico","year":"2009","unstructured":"Federico M, Bellei M, Marcheselli L, Luminari S, Lopez-Guillermo A, Vitolo U, et al. Follicular lymphoma international prognostic index 2: a new prognostic index for follicular lymphoma developed by the international follicular lymphoma prognostic factor project. J Clin Oncol. 2009;27:4555\u201362.","journal-title":"J Clin Oncol"},{"key":"2526_CR15","doi-asserted-by":"publisher","first-page":"1804","DOI":"10.1002\/cncr.22617","volume":"109","author":"TE Witzig","year":"2007","unstructured":"Witzig TE, Molina A, Gordon LI, Emmanouilides C, Schilder RJ, Flinn IW, et al. Long-term responses in patients with recurring or refractory B-cell non-Hodgkin lymphoma treated with yttrium 90 ibritumomab tiuxetan. Cancer. 2007;109:1804\u201310.","journal-title":"Cancer"},{"key":"2526_CR16","doi-asserted-by":"publisher","first-page":"386","DOI":"10.1007\/s12185-014-1636-5","volume":"100","author":"N Uike","year":"2014","unstructured":"Uike N, Choi I, Tsuda M, Haji S, Toyoda K, Suehiro Y, et al. Factors associated with effects of 90Y-ibritumomab tiuxetan in patients with relapsed or refractory low-grade B cell non-Hodgkin lymphoma: single-institution experience with 94 Japanese patients in rituximab era. Int J Hematol. 2014;100:386\u201392.","journal-title":"Int J Hematol"},{"key":"2526_CR17","doi-asserted-by":"publisher","first-page":"25","DOI":"10.2967\/jnumed.109.067892","volume":"51","author":"M Weiler-Sagie","year":"2010","unstructured":"Weiler-Sagie M, Bushelev O, Epelbaum R, Dann EJ, Haim N, Avivi I, et al. (18)F-FDG avidity in lymphoma readdressed: a study of 766 patients. J Nucl Med. 2010;51:25\u201330.","journal-title":"J Nucl Med"},{"key":"2526_CR18","doi-asserted-by":"publisher","first-page":"4643","DOI":"10.1200\/JCO.2005.12.072","volume":"23","author":"H Sch\u00f6der","year":"2005","unstructured":"Sch\u00f6der H, Noy A, G\u00f6nen M, Weng L, Green D, Erdi YE, et al. Intensity of 18fluorodeoxyglucose uptake in positron emission tomography distinguishes between indolent and aggressive non-Hodgkin\u2019s lymphoma. J Clin Oncol. 2005;23:4643\u201351.","journal-title":"J Clin Oncol"},{"key":"2526_CR19","doi-asserted-by":"publisher","first-page":"54","DOI":"10.1182\/blood-2007-01-068056","volume":"110","author":"F Morschhauser","year":"2007","unstructured":"Morschhauser F, Illidge T, Huglo D, Martinelli G, Paganelli G, Zinzani PL, et al. Efficacy and safety of yttrium-90 ibritumomab tiuxetan in patients with relapsed or refractory diffuse large B-cell lymphoma not appropriate for autologous stem-cell transplantation. Blood. 2007;110:54\u20138.","journal-title":"Blood"},{"key":"2526_CR20","doi-asserted-by":"publisher","first-page":"1543","DOI":"10.1093\/annonc\/mdp030","volume":"20","author":"JY Ngeow","year":"2009","unstructured":"Ngeow JY, Quek RH, Ng DC, Hee SW, Tao M, Lim LC, et al. High SUV uptake on FDG-PET\/CT predicts for an aggressive B-cell lymphoma in a prospective study of primary FDG-PET\/CT staging in lymphoma. Ann Oncol. 2009;20:1543\u20137.","journal-title":"Ann Oncol"},{"key":"2526_CR21","doi-asserted-by":"publisher","first-page":"325","DOI":"10.17219\/acem\/31804","volume":"24","author":"S Novelli","year":"2015","unstructured":"Novelli S, Briones J, Flotats A, Sierra J. PET\/CT assessment of follicular lymphoma and high grade B cell lymphoma. Good correlation with clinical and histological features at diagnosis. Adv Clin Exp Med. 2015;24:325\u201330.","journal-title":"Adv Clin Exp Med"},{"key":"2526_CR22","first-page":"1836","volume":"36","author":"JW Keyes Jr","year":"1995","unstructured":"Keyes JW Jr. SUV: standard uptake or silly useless value? J Nucl Med. 1995;36:1836\u20139.","journal-title":"J Nucl Med"},{"key":"2526_CR23","doi-asserted-by":"publisher","first-page":"864","DOI":"10.1007\/s00259-012-2079-y","volume":"39","author":"E Lopci","year":"2012","unstructured":"Lopci E, Zanoni L, Chiti A, Fonti C, Santi I, Zinzani PL, et al. Fanti S. FDG PET\/CT predictive role in follicular lymphoma. Eur J Nucl Med Mol Imaging. 2012;39:864\u201371.","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"2526_CR24","doi-asserted-by":"publisher","first-page":"372","DOI":"10.1080\/10428194.2016.1196815","volume":"58","author":"L Kostakoglu","year":"2017","unstructured":"Kostakoglu L, Goy A, Martinelli G, Caballero D, Crump M, Gaidano G, et al. FDG-PET is prognostic and predictive for progression-free survival in relapsed follicular lymphoma: exploratory analysis of the GAUSS study. Leuk Lymphoma. 2017;58:372\u201381.","journal-title":"Leuk Lymphoma"},{"key":"2526_CR25","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1007\/s00277-015-2553-2","volume":"95","author":"HJ Adams","year":"2016","unstructured":"Adams HJ, Nievelstein RA, Kwee TC. Prognostic value of interim and end-of-treatment FDG-PET in follicular lymphoma: a systematic review. Ann Hematol. 2016;95:11\u20138.","journal-title":"Ann Hematol"},{"key":"2526_CR26","doi-asserted-by":"publisher","first-page":"3618","DOI":"10.1200\/JCO.2016.66.9440","volume":"34","author":"M Meignan","year":"2016","unstructured":"Meignan M, Cottereau AS, Versari A, Chartier L, Dupuis J, Boussetta S, et al. Baseline metabolic tumor volume predicts outcome in high-tumor-burden follicular lymphoma: a pooled analysis of three multicenter studies. J Clin Oncol. 2016;34:3618\u201326.","journal-title":"J Clin Oncol"},{"key":"2526_CR27","doi-asserted-by":"publisher","first-page":"274","DOI":"10.1111\/bjh.13954","volume":"173","author":"TM Illidge","year":"2016","unstructured":"Illidge TM, McKenzie HS, Mayes S, Bates A, Davies AJ, Pettengell R, et al. Short duration immunochemotherapy followed by radioimmunotherapy consolidation is effective and well tolerated in relapsed follicular lymphoma: 5-year results from a UK National Cancer Research Institute Lymphoma Group study. Br J Haematol. 2016;173:274\u201382.","journal-title":"Br J Haematol"},{"key":"2526_CR28","doi-asserted-by":"publisher","first-page":"1977","DOI":"10.1200\/JCO.2012.45.6400","volume":"31","author":"F Morschhauser","year":"2013","unstructured":"Morschhauser F, Radford J, Van Hoof A, Botto B, Rohatiner AZ, Salles G, et al. 90Yttrium-ibritumomab tiuxetan consolidation of first remission in advanced-stage follicular non-Hodgkin lymphoma: updated results after a median follow-up of 7.3 years from the International, Randomized, Phase III First-LineIndolent trial. J Clin Oncol. 2013;31:1977\u201383.","journal-title":"J Clin Oncol"},{"key":"2526_CR29","doi-asserted-by":"publisher","first-page":"1093","DOI":"10.1002\/cam4.684","volume":"5","author":"B Casadei","year":"2016","unstructured":"Casadei B, Pellegrini C, Pulsoni A, Annechini G, De Renzo A, Stefoni V, et al. 90-yttrium-ibritumomab tiuxetan consolidation of fludarabine, mitoxantrone, rituximab in intermediate\/high-risk follicular lymphoma: updated long-term results after a median follow-up of 7 years. Cancer Med. 2016;5:1093\u20137.","journal-title":"Cancer Med"}],"container-title":["International Journal of Hematology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s12185-018-2526-z\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s12185-018-2526-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s12185-018-2526-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,9,9]],"date-time":"2019-09-09T23:16:20Z","timestamp":1568070980000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s12185-018-2526-z"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,9,10]]},"references-count":29,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2019,1]]}},"alternative-id":["2526"],"URL":"https:\/\/doi.org\/10.1007\/s12185-018-2526-z","relation":{},"ISSN":["0925-5710","1865-3774"],"issn-type":[{"value":"0925-5710","type":"print"},{"value":"1865-3774","type":"electronic"}],"subject":[],"published":{"date-parts":[[2018,9,10]]},"assertion":[{"value":"2 February 2018","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"1 September 2018","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"3 September 2018","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"10 September 2018","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with ethical standards"}},{"value":"Authors declared that they have no conflict of interest.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}]}}